Enzyme substitution in pancreatic disease

Area of Science:

• Gastroenterology
• Pancreatology
• Digestive Physiology

Background:

• Pancreatic enzyme substitution therapy (CEST) has limited primary indications, often relative.
• Chronic pancreatic insufficiency (CPI) with severe exocrine dysfunction (≤2% capacity) leads to significant malabsorption and steatorrhea (>25g/day).
• Pain management in chronic pancreatitis (CP) is another potential indication for CEST.

Purpose of the Study:

• To review the indications for pancreatic enzyme substitution.
• To discuss the mechanisms and considerations for effective CEST.
• To highlight the importance of patient compliance and education.

Main Methods:

• Literature review of pancreatic enzyme substitution therapy.
• Analysis of indications, efficacy, and patient-related factors.
• Discussion of pharmacological and galenic considerations.

Main Results:

• CEST is most clearly indicated for malabsorption in advanced CPI.
• Pain control in CP may be achieved with CEST, with plausible mechanistic explanations.
• Optimal outcomes require attention to galenic formulation, acid suppression, individualized dosing, and patient compliance.

Conclusions:

• Pancreatic enzyme substitution is a key therapy for malabsorption in CPI.
• CEST offers potential benefits for pain management in CP.
• Successful therapy hinges on appropriate patient selection, formulation, dosing, and comprehensive patient education, addressing socio-psychological aspects.